Single-cell based precision oncology: First steps in addressing and overcoming tumor heterogeneity

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Tumor heterogeneity is a well-recognized hurdle to successful cancer therapy, often leading to resistance and treatment failure. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Sanju Sinha, PhD
Assistant professor, Cancer Molecular Therapeutics Program, NCI-Designated Cancer Center, Sanford Burnham Prebys Medical Discovery Institute
Eytan Ruppin, MD, PhD
Chief, Data Science Laboratory, Head, Computational Precision Oncology Section, Senior investigator, Center for Cancer Research, National Cancer Institute
Table of Contents

YOU MAY BE INTERESTED IN

Artificial Intelligence can improve breast cancer detection and reduce workload on physicians, according to a new study featuring over 461,000 women. The research published in the journal Nature Medicine looked at integrating an AI tool as part of a national screening program for women without symptoms of breast cancer in Germany.
Sanju Sinha, PhD
Assistant professor, Cancer Molecular Therapeutics Program, NCI-Designated Cancer Center, Sanford Burnham Prebys Medical Discovery Institute
Eytan Ruppin, MD, PhD
Chief, Data Science Laboratory, Head, Computational Precision Oncology Section, Senior investigator, Center for Cancer Research, National Cancer Institute

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login